New FDA Drug Safety Communication on Gilenya (fingolimod)

The U.S. Food and Drug Administration is warning that a case of definite progressive multifocal leukoencephalopathy (PML) and a case of probable PML have been reported in patients taking Gilenya (fingolimod) for multiple sclerosis (MS). These are the first cases of PML reported in patients taking Gilenya who had not been previously treated with anContinue reading “New FDA Drug Safety Communication on Gilenya (fingolimod)”